Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations @RiyueSunnyBao
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
The Oncologist
3.2K posts
The Oncologist
@OncJournal
The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.
Durham, NC, USA Katılım Temmuz 2010
320 Takip Edilen25.5K Takipçiler
Early dexrazoxane use lowers cardiotoxicity risk in adults w/ sarcoma receiving high-dose anthracyclines. Findings support benefit of early dexrazoxane to enable safer chemo delivery; prospective validation needed.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
Study finds most pts w/ GI cancer are malnourished at diagnosis. Poor nutritional status strongly links w/ fatigue, low physical activity, & reduced QoL, showing the need for nutrition support before therapy.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
ICI-related gastritis is a rare ir-AE for which diagnostic criteria & management guidelines are lacking. Here an approach to diagnosis & management (mostly without corticosteroids) is proposed.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
Pt w/ metastatic #ColorectalCancer w/ pCR at primary tumor after preop therapy have favorable long-term outcomes: 62.2% 2️⃣-yr PFS & 84.5% 3️⃣-yr OS. Those w/ colon CA showed esp. strong survival trends vs rectal CA.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
HER2-targeted therapies are not standard treatment for non-breast solid tumors, but this study shows pyrotinib as a potential treatment option for later-line therapy of HER2+ solid tumors, esp colorectal cancer.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
An asynchronous electronic consent for improving consent in research among patients with cancer
@susanebates @gbanna74 @PasRescigno @jonathanloree
doi.org/10.1093/oncolo…
English
Neoadjuvant endocrine therapy + CDK4/6 inhibitors shows similar response rates to standard chemotherapy in HR+ locally advanced #BreastCancer & may benefit chemo-insensitive tumors w/ improved tumor shrinkage.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
New research finds #melanoma pts treated w/ ICIs show ⬆️decline in psoas muscle density compared w/ those not on ICIs, independent of kidney function, highlighting potential muscle-related effects of #immunotherapy.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
Dr. Kleinhenz et al describe a case of treatment of FGFR2 fusion-positive biliary tract cancer with lenvatinib after progression on pemigatinib and futibatinib.
@susanebates @gbanna74 @PasRescigno @SebLange
doi.org/10.1093/oncolo…
English
New review: A multidisciplinary team approach is 🔑 in supporting personalized decision-making in well-differentiated #ThyroidCancer.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
In a multicenter real-world study, combining #SBRT ✚ PD-1 inhibitors improved tumor control & long-term survival vs SBRT alone in unresectable HCC, with manageable toxicity & no major increase in severe AEs.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
BEVATOMOX Phase II: Raltitrexed + oxaliplatin (TOMOX) + bevacizumab showed comparable efficacy & safety to standard mFOLFOX6 + bevacizumab in 2nd-line metastatic #CRC, offering a potential alternative regimen. #crcsm
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
The QuICC trial of a quadruple #immunotherapy regimen in mismatch repair-proficient mCRC showed that combining multiple immune agents can elicit clinical activity in tumors traditionally resistant to immunotherapy.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
Meta-analyses in RASwt metastatic #ColorectalCancer: triplet chemo + anti-EGFR improves response vs chemo alone, but no clear survival advantage over other targeted combinations. Careful patient selection remains key.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
In this largest real-world cohort of metastatic #TNBC to date, the clinical benefit & manageable safety of sacituzumab govitecan seen in the ASCENT trial was confirmed in routine practice.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
Survey: Community MDs prioritize OS & QoL in choosing 3rd-line drugs for metastatic #ColorectalCancer. Most favored trifluridine-tipiracil+bevacizumab.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
The role of patient navigation programs in early cancer care in Mexico: a multi-case qualitative study
@susanebates @gbanna74 @PasRescigno @ElysseBg
doi.org/10.1093/oncolo…
English
Adjuvant chemotherapy improved survival for patients with an LNR below 11% but provided no benefit for those with higher LNRs (LNR threshold of 11% can be used to personalize treatment).
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English
FDA GI cancer drug approvals rely on #accelerated pathways, surrogate endpoints, and #singlearm trials. From 2006–2025, survival gains were modest, raising concerns about meaningful patient outcomes #GIonc
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo…
English